[Further study on gentamicin in pediatrics (author's transl)]

Area of Science:

• Pediatric Infectious Diseases
• Antibiotic Chemotherapy
• Pharmacology

Context:

• Gentamicin (GM) is an aminoglycoside antibiotic.
• Pediatric infections require effective and safe treatment options.
• Assessing antibiotic efficacy and safety in pediatric populations is crucial.

Purpose:

• To evaluate the clinical efficacy and safety of intramuscular gentamicin in pediatric patients with various infectious diseases.
• To determine optimal gentamicin dosage regimens for different pediatric infections.
• To identify gentamicin's potential role as a first-line antibiotic in specific pediatric bacterial infections.

Summary:

• Intramuscular gentamicin demonstrated 100% clinical effectiveness in 16 pediatric patients across diverse infections, including septicemia, meningitis, and pneumonia.
• Dosage adjustments, including increases to 5-8 mg/kg/day, yielded satisfactory results without observed renal, hepatic, or ototoxic adverse effects within 18 days.
• Gentamicin is recommended for infections caused by Staphylococcus and gram-negative bacilli, particularly in penicillin/cephalosporin-hypersensitive children, though further safety studies on dosage and duration are warranted.

Impact:

• Establishes gentamicin as a highly effective first-line treatment for various pediatric bacterial infections.
• Provides evidence for safe and effective gentamicin dosing strategies in children.
• Supports the use of gentamicin in pediatric patients with hypersensitivity to other antibiotic classes.